Merck & Co (MRK) Earnings Date & Reports

Key Takeaways

• Merck & Co. (MRK) is scheduled to report second-quarter 2026 results on Tuesday, August 4, before the market opens, followed by a conference call at 9:00 a.m. ET.
• Wall Street consensus projects Q2 revenue of approximately $16.39 billion, which would represent roughly 3.7% year-over-year growth from $15.81 billion in the same quarter last year.
• GAAP (Generally Accepted Accounting Principles) earnings per share estimates remain wide-ranging due to one-time acquisition-related charges; the Yahoo Finance consensus stands at approximately -$0.15 per share, down sharply from $2.13 in Q2 2025.
• Investor focus will center on Keytruda sales trends, the commercial uptake of newly launched products including Winrevair and Keytruda QLEX, and any updates on the proposed acquisition of Terns Pharmaceuticals.
• Merck has exceeded Wall Street consensus EPS estimates in eight consecutive quarters and has a strong track record of meeting or beating revenue expectations.
• Shares have gained approximately 2.6% over the past month, with the stock trading near $130 and an average analyst price target of $135.19.

Earnings Context and Why It Matters

Merck enters its Q2 2026 report at a pivotal moment. The Rahway, New Jersey-based pharmaceutical giant is navigating a complex landscape: its blockbuster oncology franchise, led by Keytruda, continues to deliver robust growth, while the company simultaneously manages significant one-time charges tied to strategic acquisitions. In Q1 2026, Merck posted revenue of $16.29 billion — a 4.9% year-over-year increase that comfortably beat estimates — but reported a GAAP net loss driven by a $9 billion charge related to the Cidara (Sedera) acquisition. With the proposed Terns Pharmaceuticals deal expected to add another substantial one-time R&D (research and development) charge, investors are eager to assess underlying operational momentum. This report will also offer critical insight into the commercial trajectory of newer products that are central to Merck's post-Keytruda patent-expiry strategy, with the drug's U.S. exclusivity set to expire in 2028.

Earnings Expectations

Analyst consensus, as compiled by Yahoo Finance from five covering analysts, points to Q2 2026 revenue of $16.39 billion, with individual estimates ranging from $16.23 billion to $16.70 billion. This would mark a reversal from the 1.9% revenue decline recorded in the year-ago quarter and imply approximately 3.7% top-line growth. On the bottom line, the GAAP EPS consensus sits near -$0.15, heavily distorted by acquisition-related amortization and charges. Non-GAAP estimates tracked by several research firms cluster in the range of $1.83 to $2.06 per share, against $2.13 in GAAP EPS reported in Q2 2025.

Keytruda remains the central revenue driver. Wall Street expects the oncology franchise to generate roughly $8.06 billion in global sales this quarter, reflecting approximately 1.3% growth from the prior-year period. Meanwhile, Gardasil sales — which declined 22% in Q1 — will be closely scrutinized for signs of stabilization. Other metrics under the microscope include alliance revenue from Lynparza and Lenvima, the performance of the hospital acute care portfolio (Bridion, Prevymis, Zerbaxa), and the early commercial trajectory of Keytruda QLEX, which recorded $128 million in Q1 sales following its launch.

Merck raised and narrowed its full-year 2026 guidance in April, projecting revenue of $65.8 billion to $67.0 billion and non-GAAP EPS of $5.04 to $5.16. Any revision to these ranges will be a key market-moving factor.

AI Screener

As investors prepare for Merck's earnings release, tools that streamline the research process are increasingly valuable. Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery platform designed to help traders and investors filter the market using a broad range of customizable criteria. Users can scan thousands of equities based on technical patterns, fundamental metrics, industry classification, market capitalization, volatility profiles, and proprietary AI-driven signals. The screener is built to surface trade ideas, breakout candidates, and trending stocks far more efficiently than manual methods, making it a practical companion for both active traders and longer-term investors monitoring earnings season. Explore the AI Screener to see how data-driven filtering can sharpen your market research.

Market Reaction and Investor Sentiment

Sentiment heading into Merck's Q2 report is cautiously optimistic. The stock has appreciated roughly 2.6% over the past month, outpacing the broader pharmaceuticals segment, where share prices have been largely flat. Trading near $130, MRK sits below its average analyst price target of $135.19 but within range of its 52-week high of $135.05. The company's beta of 0.20 — a measure of volatility relative to the broader market — suggests the stock tends to be less reactive to macro swings, placing greater emphasis on company-specific earnings outcomes.

Key risk factors that could influence the post-earnings reaction include any downside surprise in Gardasil sales, weaker-than-expected Keytruda growth, or disappointing updates on pipeline assets. Conversely, a guidance raise, stronger new-product uptake, or positive commentary on the Terns acquisition could provide a catalyst. With eight consecutive quarters of EPS beats, the bar for an upside surprise on operational metrics is well established.

Forward Outlook and Key Factors to Monitor

Beyond the Q2 headline numbers, several forward-looking themes will shape Merck's investment narrative in the months ahead.

The first is the Keytruda patent cliff. With U.S. exclusivity expiring in 2028, investors are increasingly focused on how effectively Merck is building a post-Keytruda growth story. Keytruda QLEX — a subcutaneous formulation that offers a more convenient dosing option — represents one avenue to extend the franchise. Its permanent J-code, effective April 1, 2026, is expected to support broader provider adoption, and commentary on its uptake trajectory will be closely parsed.

The pipeline remains another critical area. Merck secured FDA (Food and Drug Administration) approval for Edvinso (doravirine/islatravir), a once-daily two-drug HIV regimen, and gained priority review for Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer, with a PDUFA (Prescription Drug User Fee Act) target date of October 10, 2026. Additional regulatory decisions on WELIREG combinations and the KEYTRUDA plus Padcev regimen are expected in the coming months. Any updates on these timelines or new data readouts could materially influence sentiment.

The proposed Terns Pharmaceuticals acquisition adds another layer of complexity. Management has flagged that the deal will bring a one-time R&D charge of approximately $5.8 billion and a near-term EPS drag of roughly $0.12 in 2026. Investors will want to hear a clearer articulation of the strategic rationale and long-term revenue potential of TERN-701, the lead asset targeting hematology indications.

Finally, cost management and margin trends warrant attention. Merck guided for a gross margin of approximately 82% and operating expenses of $36.0 billion to $36.8 billion for the full year, excluding the Terns impact. Any deviation — particularly amid inflationary pressures and R&D investment requirements — could reshape earnings expectations for the back half of 2026.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations